Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.

Abstract

The prognostic nutritional index (PNI), an indicator of nutritional status and systemic inflammation, is associated with survival in several types of lymphoma. The purpose of this study was to investigate the prognostic value of PNI in diffuse large B cell lymphoma (DLBCL). With three hundred and ten patients were enrolled, the median level of PNI was 45.90 (range 25.30-139.70). According to the receiver operating characteristic (ROC) curve, 44.85 was determined to be the best cutoff value to divide patients into two different groups. With a median follow-up of 33.3 months (range 3.5-118.5), compared with the high PNI group, the 3-year and adjusted 3-year progression-free survival (PFS) and overall survival (OS) were worse in the low PNI group (all P < 0.050). Multivariate Cox analysis suggested that low PNI was an independent risk factor for PFS (hazard ratio (HR) 2.196, 95 % CI 1.197-4.030, P = 0.011) and showed a tendency to predict inferior OS (HR 1.918, 95 % CI 0.932-3.948, P = 0.077). Furthermore, PNI combined with other significant prognostic factors to build a novel prognostic index, namely NPI, was more accurate than the National Comprehensive Cancer Network international prognostic index (NCCN-IPI) to predict worse PFS and had a similar effect on predicting OS. All these findings suggested that PNI, as a novel available biomarker, was of prognostic significance in DLBCL patients.

• Authors: Jie He, Hua Yin, Yi Xia, Jia-Zhu Wu, Jin-Hua Liang, Hua-Yuan Zhu, Lei Fan, Jian-Yong Li, Li Wang, Wei Xu
• Journal: Leukemia research (Leuk Res) Vol. 110 Pg. 106664 (11 2021) ISSN: 1873-5835 [Electronic] England
• PMID: 34271293 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Nutrition Assessment
• Prednisone (administration & dosage)
• Prognosis
• ROC Curve
• Retrospective Studies
• Rituximab (administration & dosage)
• Survival Rate
• Vincristine (administration & dosage)
• Young Adult